We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

175 hedge funds and large institutions have $650M invested in Intercept Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 58 increasing their positions, 52 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 52

5% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 37

1% less funds holding

Funds holding: 177175 (-2)

25% less call options, than puts

Call options by funds: $36M | Put options by funds: $47.8M

45% less capital invested

Capital invested by funds: $1.18B → $650M (-$528M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
175
Holders Change
-2
Holders Change %
-1.13%
% of All Funds
3.1%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
35
Increased
58
Reduced
52
Closed
37
Calls
$36M
Puts
$47.8M
Net Calls
-$11.8M
Net Calls Change
-$7.54M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$86.4M -$7.63M -230,307 -6%
Vanguard Group
2
Vanguard Group
Pennsylvania
$69.9M +$2.95M +89,130 +3%
State Street
3
State Street
Massachusetts
$63M +$28.5M +860,697 +51%
BlackRock
4
BlackRock
New York
$61.7M +$10.6M +318,773 +15%
First Trust Advisors
5
First Trust Advisors
Illinois
$48.3M +$14.8M +447,294 +30%
JP Morgan Chase
6
JP Morgan Chase
New York
$32.6M +$2.11M +63,665 +5%
Ameriprise
7
Ameriprise
Minnesota
$29.9M +$11.6M +349,254 +41%
Goldman Sachs
8
Goldman Sachs
New York
$24.7M +$11.7M +353,079 +54%
Macquarie Group
9
Macquarie Group
Australia
$17.4M -$2.46M -74,275 -10%
Jacobs Levy Equity Management
10
Jacobs Levy Equity Management
New Jersey
$11.8M +$4.39M +132,478 +38%
Renaissance Technologies
11
Renaissance Technologies
New York
$10.8M +$6.37M +192,300 +79%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$10M -$5.78M -174,400 -30%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$10M +$103K +3,112 +0.8%
Voloridge Investment Management
14
Voloridge Investment Management
Florida
$9.17M +$1.87M +56,485 +18%
EAM
15
EULAV Asset Management
Florida
$8.28M +$6.1M +184,000 +122%
AGA
16
Altrinsic Global Advisors
Connecticut
$7.79M +$933K +28,155 +10%
Morgan Stanley
17
Morgan Stanley
New York
$7.52M +$8.19M +247,065 +430%
Northern Trust
18
Northern Trust
Illinois
$7.37M -$295K -8,895 -3%
Two Sigma Investments
19
Two Sigma Investments
New York
$6.85M +$2.04M +61,480 +28%
Citadel Advisors
20
Citadel Advisors
Florida
$5.42M +$1.49M +44,949 +26%
Bank of America
21
Bank of America
North Carolina
$5.07M +$382K +11,541 +6%
Charles Schwab
22
Charles Schwab
California
$5.01M +$54K +1,631 +0.8%
Norges Bank
23
Norges Bank
Norway
$4.78M +$732K +22,076 +13%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$4.47M +$2.25M +67,853 +60%
Assenagon Asset Management
25
Assenagon Asset Management
Luxembourg
$4.41M -$11M -331,878 -65%

ICPT Hedge Fund Activity: Q4 2020 in Review

175 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2020, worth a combined $650M — down 45% from $1.18B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of ICPT and 35 opened new positions — a net loss of 2 holders — while 52 trimmed existing stakes and 58 added.

The largest buyer was State Street, adding an estimated $28.5M. The largest seller was Boxer Capital, exiting entirely with an estimated $48.8M sold.

  • 175 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2020, down from 177 in Q3 2020.
  • Funds reported $650M of Intercept Pharmaceuticals, Inc. stock for Q4 2020, down 45% quarter-over-quarter.
  • 35 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2020 and 37 closed out, a net change of -2 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2020 was State Street, an estimated $28.5M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q4 2020 was Boxer Capital, an estimated $48.8M sold.

Based on aggregated 13F filings for Q4 2020.